Loading candles…
Balaxi Pharmaceuticals Ltd is an intellectual property rights-based pharmaceutical company operating within the pharmaceutical industry. It produces, stocks, sells, and supplies branded medicines, generic medicines, and branded generics. The company employs an asset-light business model with a focus on frontier markets in Africa, Central America, and Latin America, including countries such as Angola, Guatemala, and the Dominican Republic. Balaxi Pharmaceuticals manages the entire process from product registration and sourcing to last-mile delivery. It leverages a deep supply chain and distribution network to provide affordable healthcare solutions across these regions. No information is available regarding its incorporation year, founders, key management, subsidiaries, or stock exchange listings.
This page is a live market overview for BALAXI PHARMA LTD (BALAXI) on the NSE. As a listed security, BALAXI PHARMA LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for BALAXI before placing trades on tick2trade.
As of the latest feed, BALAXI last traded at ₹23.58 on NSE, up ₹0.46 (1.99%) from the previous close of ₹23.12. Today's session range is ₹22.86 – ₹23.58, against a 52-week band of ₹15.2 – ₹47.71. Traded volume today stands at 34.09K shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for BALAXI in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether BALAXI is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for BALAXI PHARMA LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in BALAXI. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated BALAXI option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Unaudited Results - Q1 & FY26 | To consider and approve the unaudited standalone and consolidated financial results of the Company for the first quarter ended 30th June, 2026 of the Financi… | 5 Aug 2026 |
| Audited Results - Q4 & FY26 | To consider and approve the audited financial results (Standalone and Consolidated) for the fourth quarter and financial year ended March 31, 2026 and other… | 28 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and other business matters | 28 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and other business matters | 11 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 5 Aug 2025 |
| Audited Results - Q4 & FY25 | To consider and approve the audited financial results (Standalone & Consolidated) for the fourth quarter and financial year March 31, 2025 and other business… | 30 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.